Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo
For women with PCOS, weight loss may be associated with improvements in ovulatory function, though this represents an off-label use and women should receive appropriate contraception counseling given tirzepatide's potential interaction with oral contraceptives
Thats because the two formulations seem to target different patient segments
The Precision Peptide Genetic Test ($298) maps variants in GIPR pathways that influence your receptor sensitivity and inflammatory response to dual-agonist activation
Nausea, vomiting, diarrhea, and constipation are the most frequently reported issues with both peptides
Heres what Midis medical experts recommend: Lose weight: Consider GLP-1s, like semaglutide or tirzepatide